Company Registration Number- 8013670 The Charity Registration Number is :_ 1147506 Ocular Melanoma UK Report and Accounts 31 March 2024
Ocular Melanoma UK Report and accounts for the year ended 31 March 2024 Contsnts Page Charlty infonnatlon Tru$t••s' Annual Repc*rt Statemenl of directors. re#ponslbllltl•s Ind8pend•nt Aetountant's Report 13 Fund$ Statements.". Statement of Financial Activitie5 Statement of Financial Activrties- Prior Year statement Movements in hjnds Income and Expenditure account 15 17 18 Balance 5hè8t 19 Notes to the a¢counts 20
Ocular Melanoma UK Company Reglstration Number- 8013670 Trustees, Annual Report for the year ended 31 March 2024 The Trustees present their Report and Accounts for the year ended 31 March 2024. which a150 compiists the Directors, Report required by the Companiès Act 2006. Reference and adminlstrative details The eharlty name. The legal narne of the charity i5- Ocular Melanotna UK. The charity is also known by its operating name. OculaT Melanorna UK. Th• charllys areas operatlon and UK ¢harltable re9lstratlon. The chatty is wistered In England 8 Wales wth the Charity Commission In England & Wales ICCEWI with charity number 1147506. The charity doe5 not OP8fate in any ovèrsèas Jurisdictions. Lègal structure of the ¢harlty The tharity Is constltut•d as a company limrted by guarantee, registered under the Companie5 Acts . The goveming document of the charity is the Memorandum and Artides of Association establishing the mpany undef cornpany legislation. The goveming document is ¢Jated 26 March 2012 Updated Articles of Association and Special Resolution a dated 20th August 2024 There are no restrictions in the governing do¢uments on the operation of the Charity or on its investment powers other than those imposed by Charity Law. By operation ol law all trustees are dire¢lors under the Companies Act 2006 and all director5 are trustees under Charitie5 legislation snd have iesponsibilrties, as suth, under both cotnpany and charity legislation. The trustèes a all individuals. The prlnclpal operatlng •ddf¢S$, telophong number, ernail and web addre¥$es of the charity ar•.-- 139 Langley Road Slough. Bethshi UK. SL3 7DZ Telephone 01753 357771 Email Add$$ info@omuk.org Web Add$$ wv.omuk.org The registered office of the chanty for Companies Act purposes Is the Same as the operating address shown above.
Ocular Melanoma UK Company Registration Number- 8013670 Trustees. Annual Report for the year ended 31 March 2024 The Trustees In office on the date the reportwas approv•d w•r•:. Mr Neil Pearce Mrs Alison Benjamin Mrs Jtsanne Morgan- Chair Mr Gianfranco De Franco Mr Colin While Mrs Ch8rfotte Edwards- Tr8asurei Thg followln9 porson8 Served as Trustse8 durrng the year 8nd•d 31 Idarch 2024:. The twstees who served as a trustee In the reporting period. and, if applicable, their dates of appointment Of signation during the year were".- N&me Mr Neil Pear Mrs Alison 8enjarnin Mrs Joanne Morgan- Chair Mr Giantranco De Franco Mr Colin White Mrs Charfotte Edward5- Treasurer All the trust8es arè also members ol the charty. Appolnted Re$ignedlRetired
Ocular Melanoma UK Company Regi3tration Number- 8013670 Trustees, Annual Report for the year ended 31 March 2024 Objects and a¢tlvltles of the charity The purposes of the Charity. Ocular Melanorna UK Is the only UK charty Solely dedicated to supporting people affected by ocular melanoma. We have been helping people Sin 2011 wth this rare cancer so they could talk to others about their cancer diagnosis and adjust to life il they experien vision Ioss. We are detemiined to drive improvements so people can live well wth ocular melanoma. This can be a devastating c8ncer so we are working to ensure people have access to effective treatments and that clear pathways a in place, all while striving to provide specialist support to people who need it. What 1$ otutar melanoma? Ocular melanoma is a canr of the eye. We know approximately 750 people In the UK will hear they have ocular melanoma each year and those people are likely to need support. We know we have hundreds ol people in the UK liwng with ocular rnelanoma who may need support adju5tsng to life after th81r diagnosis. - We also know one In every hvo people will hear they need ffUrtr treatment if the cancer spad$ We know that no one should face this terrifying tirne alone. Ocular melanoma includes fv40 Cancers. uveal and conjunctival melanorna. Uveal melanorna include5 th8 ir15, choroid or ciliary body. Both types of ocular melanoma can metastasise {spal to other organs, with the liver typically involved in 90°/o ol uveal melanorna cases. If ocular melanoma spreads to another organ, it is currently in¢urable. Some treatments extend life expectancy and irnprove th8 quality of life for some pat18nts, but patient5 can face difficulties accessing these treatments. Ocular melanoma Is usually discov8r8d dunng a routine eye examination. or when the patient experiences symptoms and goes to their GP or optometrist. If the optometrist or GP suspects rancer. they should urgently refer the patient to their local ophthalrnology departrnent. should they agree with the Conrn, they 11 refer to one ol four specialist centres". Glasgow, Liverpool, Sheffield or London. Vthy Is Ocular Melanoma UK needed? People with ocular melanoma Can feel very ally. The condition is 50 ra and the prognosis often 50 overwhelming. that patients frequently report feeling Isolated. Ocular Melanoma UK came about to provide both support and a voice for those with this rare cancer. We bring people together across the cguntry and provide UK-specific information. Ocular Melanorna patients afe often excluded from skin rnelanoma trials. so te5earch is limrted. Treatments ara progressing. but many people face bamers to Celn9 treatments Ocular Melanorna UK is iaising the d15ea5e profile within the medical community and decision-makers. We work lo improve patnts, access to effective treatments. and eventually financially support research.
Ocular Melanoma UK Company RegI5tration Nurnber- 8013670 Trustees, Annual Report for the year ended 31 March 2024 Our a1rn5 and obl•ctlv•s OUT Vision is 8 worfd whera people wth ocular melanoma can Iwe. and live w811. Our Mission is lo advocate for changè by uniting against ocular melanoma cancers so that every P8rson receives the treatment. infomiation and support they need. Ocular Melanorna UK'S charitable objectives are. 1. To primarily promote and protect the physical and rnental heatth of people with o¢ular melanoma and their families in the Unrted Kingdorn through support. information, education and practical advicè. 2. To support research into ocular melanoma and to publish the useful results. The main activities undertaken during the year to further the charity s purpose for the public benefit. Ocular Melanoma UK provides members and oth8rs wth current infomation and non-dinical advice and support through various channels. People tell us they wish they learnt about U5 when they %%tre first diagnosed as ihey appreciate the infomiatson and support we provide. This means a great deal to them. so we have planned several projects to increase our reach so that On someone is diagnosed. they learn about Ocular Melanorna UK. thè seM¢es we prowde, and that we can encourage treatment pathways to be developed to ease the pressures people face. During the year, we supported our community by offering thè folltswing sèrwces. To Improve Support Emotional & Practical Support We recruited a dedica18d Helpline Adwsor who Is supporting MO people through our helpline and manages our online community support groups whi¢h are open to anyone affected by this cancer. These weekly meetings provide a safe place foi p80ple to give and receive support wrth any difficulties they f8ce. Psychological Support Coniinued to provide members wth timely 8 fvnded professional support with a specialist Health Psychologist to ease the impact this diagnosis can have. This allows patients and loved ones throughout the UK to a¢$$ up to six fund8d sessions. Health Inform8tlgn We gained pif-tick Jccredilation so our health infomiation 5 easily recognised as a trusted source of information anij reviewed by ¢linicians to ensure It Is clinically accurate and written in conjunction with patients so it contains Inforrnation that they would find useful. Our first booklet Is now available on our website for people btrith metsstatic disease and we will be 18unching the next booklets about the condition and receiving treatment for the primary tumour 5horUy. Community Support As mentioned above, we run regular online session5 for people to come together to remove isolation and facilitate peer-t&peer support. We h8V8 also Increased the number of local ambassadors so that people can meet other mèmbèrs throughout the UK in person.
Ocular Melanoma UK Company R8gistrabon Nurnbar- 8013670 Trustees. Annual Report for the year ended 31 March 2024 To Build Knowl•dg• Confeienct We held a two-day conference which was very well attended by patients and family members. W$ had record number of people who hadn't attended 8 conference before and for some, it was the first time they rnet others wth the same condition. which is a huge help in ilsell. We also had some of the leading eXP8rts in their field share their knOedge wth us. Every year, we ensure these talks art recorded and available after the event so the latest knoedge is easily shared. W8bsit8 We have launched a new webSle which now meets 8¢SSIbl11ty criteria, www.omuk.org. We have launched this in ph858s so that all cancer-related information adhere5 to pif-tick quality health information standards and have now begun work on building a soUl for people to find details of the clinical trials they could be eligiNe for and we are building an area for clini¢ian$ to find information 8asily. Ocular Melanom8 October In October 2024. we launched Ocular M81anoma October, a month-long campaign to raise awareness about oculai melanoma and provide support to those affectecl by thi$ rare cancer. The campaign featured educational content. comrnunity events. and culrninated In the fit5t Ocular lan0ma Day on 10 October, marking the charity's 15th anniversary. 11 resulted in a fourfold In¢ase In our social rnedia reach and connected individuals nationwde through In-person meeting5. Th15 success laid the foundatson for an expanded awareness Initiativo next year, with fun¢Jing already secured. Ocular Melanoma October will now become an annual tradition to amplify our impact and ensure no one faces ocular mèlanom8 alona. We produce a regular bullehn for our members giving update5 on our work, how to access the services provide, and importandy, Infofmatson on how people can share their experience with us or de¢ision-m8kers to drive improvements. Advocacy This has been a 18198 part of our work as NICE felt a new drug shou¢d not be made available. We Suc$$fullY appealed this decision and it was recently announced that this new treatment. Tebentsfusp wll be 8vailable to p8opl8 on the NHS. We continued to Invtslve our community at every stage by running focus groups and we worked closely with patients so they coukl attend the meetings and explain to th8 committee what it W85 like to live wth this Condition. One of our members share(I her experien of taking the nèw drug through the clinical trial and this insight was incredibly useful for the committee. Ra Cornmunity Ocular Melanoma UK is a member of Cancer52 anLI Genets"c Alliance and regularly attends NHS England Cancer Charity meetings so key messages can be communicated to our community. but also allow5 US to Communicate the needs of people affected by ocu18r Melanom8 to decision-makers. Our CEO also work5 with Melanotna Patient Network for Europe and usemydala and sits on various projects to improve the lives of people wth this cancer.
Ocular Melanoma UK Company Reglstration Number- 801 70 Trustees, Annual Report for the year ended 31 March 2024 To Drlve Rg$earch Clinical Advisory Panel We have continued to work wth our dinical ad¥ASOry panel to gan their thoughts on how to resolve are8S that are Important to patients and to ensure the inforrnation we provide 15 clinically accurate. Resèarch applications We supported several research applications that we fèlt would benefit people and met wth oryanisations interested in 18aming about the irnpact of this caThr. Al times it was appropriate for us to lead those conversations. but where Companies were interested in talking to patients dirady. we reviewed the questions that would be asked and offered our sUPPOrt to the people Involved. Data We hav8 worked to improve the data routinely available to re$earcher5 and bodies such as NICE & SMC and wll confynue to push for belter data Collection and sharing of data 50 that the need5 of patntS are deady understood. A¢$$ to Medicines We continued to build relationships with pharmaceutical companies who have an interest in this cancer to increase the number of trials available to people and to inCaSe the possibility of effective treatments being made availab to people. We SuesSfullY appealed a decision by NICE to not rèeommènd a nèw drug and ara very pleased that patients can now le1ve this treatTnenl on the NHS. We continue to encourage NHS England to allow chem058t to be funded and have supported patsents whilè they appeal to private medical cornpani85 to have their decisions overturned. Patient Need We have expanded oui reach so that more organisation$ understand that the needs of rare canr patients are not being met Mrith the Current focus on improvin9 rnortality In the UK. We do this through working with orqanisations that share common ooals and enable us to have a voice at a national level. All this was achieved with the support of our donofs and everyone who fundraised for us. We are InC1b1Y grateful to everyone for their 8fforts over this challenging year as it enabled us to continue our work and support people through some very difficutt times. The tiustees have had regard to the Charity Commission's 9uidan¢e on publi¢ benefft in m8naging t a¢tivitie$ of the charity
Ocular Melanoma UK Company Registration Number- 8013670 Trustees, Annual Report for the year ended 31 March 2024 Structure, governance and rnanagement of the charty The methods used to recruit and appoint new charity trustees. Govèrning Doeumènt The organisation is a ¢harilable company limited by guarantee, incorporated on 30 March 2012 andregi5tsred as a charity on 30 May 2012. The company wa5 established under a Memorandum ol Assotsation which established the objects and powers of the charitable company and is governed under its Articles of Association. Management Commlttee Our CEO was a twstee of the charrty up until 31103r23 and this was approved by the Charity Comrnis5ion. All other Trustees gave and continue lo give their time voluntanly and received no benefits from the charity. Any exp8n5e5 reclaimed from the charity a set out in note 8 to the accounts. Trustees serve for up to three years and may be re-elected at the Annual General Meeting.The Board of Directors. together with the CEO, acts as the Man8gement C(xnmrtteè. Trustee Indu¢tlon Trust8es have been appointed based on their ability to lead the Charity on behalf of the membership. and are a mix of people who either have existing knowledg8 of Ocular Melanoma. either as rnedical professional or patient or family of patient. or who bring nècessary professional expertise. Trustees are also directors registered with Companies House. A comprehensive trustee information pack is Supplied to each trusto6, togèthèr wth cross-ferenCeS to the guidano published by the Charity Commission Ifor trustees) and by Companies House Ifor directors). Organl$atlonal Structure The Management Committee 13 responsible for the strategic direction and policy of the charty. The CEO has delegated re5pon51bility from the Board for the overall operation of the charity. B8nker5 CAF Bank - Kings Hill. Wesl Malling. Kent. ME19 4JQ National Westminster Bank Plc. Earls Court, Enfield CSC, Lee House, Bairs Road. Middlesex, EN1 1FO Shawbrook Bank. Lutea House. Wa[Y Hill Bu5in8s$ Park, The Driv6. Great Wailey, Brentwood. Essex CM13 3BE
Ocular Melanoma UK Company Registration Nurnber- 8013670 Trustees, Annual Report for the year ended 31 March 2024 Financlal review The charitys financial position at the end of the year ended 31 March 2024 The finanaal position of the chanty at 31 March 2024 and comparaty've$ for the prior period, a5 rnore fully detailed in the account5, can b8 surnrnarised as follows".- 2024 2023 Ntt incom• 16881 111.8051 Unrestricted Revenue Funds available for the general purposes of the charity 41.408 54.910 Restricted Revenue Funds Total Restricted Funds 36.607 23,793 23,793 36.607 Total Fundg 78.015 78,703 Financial review of the position at the reporting date, 31 March 2024 The tiustees corlsider the financial performan by the ¢harity during the year to have been satisfactory.
Ocular Melanoma UK Company Registiats"on Number- 8013670 Trustees, Annual Report for the year ended 31 March 2024 Policies on reseryes This reserves policy aims to e5t8blish gu1dèlines for the appropriate level ol SerVeS that Ocular Melanoma UK should maintain. The reserves policy will help ensure that Ocular Melanoma UK has the financial resour$ to fulfil it5 rnission and objectives, respond to emergencies. and manage risks. The serveS pOl¢Y will also provide transpartncy and accountability to Ocular Melanoma UK'S stakeholclers. including donors. volunteers. staff, and beneficiaries. Natuit of restrves.. For the purposes of thi5 policy, reserves are defined as funds that are held in excess of the Immediate needs of Ocul81 Melantsma UK. Reserves indude both unrestricted and restricted ftjnds. Re5erv8s Guidelines". 1. Target Resefves.. Ocular Melanoma UK should maintain 8 target reserve level equivalent to at least six months of operating expenses. The target reserves will be reviewed annually and a¢Jiusted as needed based on Ocular Melanoma UK'S financial situation, risks, and opportunities. 2. Minimum Reserves". Ocular Melanoma UK shoukl maintain a minimum level of reserves that is equivalent to three month5 of operabng expenses. The minimum reserves wll be reviewed annually and adjusted 8S needed based on Ocular Melanoma UK'S financial srtuation, risk5, and opportunities. 3. Use of R8S8fves Reserve5 should only be used for specific purposes, such as emergencies. unexpected expenses. or to support new initiatives. Reserves should not be used to cover ongoing operational defitsts or to fun¢J programs that are not sustainable. 4. Investrnent ol ReseNes'. Reserves should be invested in a Pfudent rnanner that balances saf8ty, liquidity. and yield. The investment strategy should be reviewed annually and adsustad as né•de(I based on Ocular Melanoma UK'5 financial situation. risks. and opportunities. 5. Reporting on Reserves. Ocular Melanoma UK will r8POrt annually on the status of its rtserves in its financial statem8llts.This reserves policy ensu$ that Ocular Melanoma UK has the financial reSoUrS to fulfil Its mission and objectives. respond lo emergencies. and manage risks. The policy prowdes guidelines for the appropriate level of r88erves, the use and investment of reserves. and porting on reserves. The policy will reviewed annually snd adjusted as nèedèd based on Ocular Melanoma UK'S financial situation, risks, and opportunities. Availability and adequa¢y of ass•ts of each of the funds The board ol trustees is satssfied that the ¢harity's assets in each fijnd are available and adequate to lulfil its obligations in re$pe¢t of each fund.
O¢ular Melanoma UK Company Regi5trats'on Number- 8013670 Trustees, Annual Report for the year ended 31 March 2024 Plans For the Future Summary of plans for the futuro and the trustee$. perspe¢tive of the future directlon of th• eharity. We strive to improv8 the car8. treatment 8nd support patients receive. We will continue our work $0 that once someone is diagnosed, they leam about Ocular Melanorna UK & the services w8 provide, and that treatment pathways are developed to ease the pressures that we know people fa. We Identified several ways to du these pressures. buikling our small charity so it ¢an help people and their families through these difficult tirne5. In addition to the servi$ outlined earlier in this report. we will continue to focu5 efforts tts Reduo delays in accessing treatment for metastatic disease and I¢aSe our serwces that reduce isolation and d15t1è5S. We wll do this by Ensuring people can easily find ¢linirAI trials known to us 85 these will be 5h8red on the new website. This remains incredibly irnportant as there Is no other resour that shows all the trials that could be useful to our patients. Representing our community at NICE, SMC & NHS r8viewE SO that treatrnents that can help our community become available lo the patients that nee(J them. Continuin9 the development of a suite of Irteratu with infotmation that our community feels is important. and ensuring we Continue to meet pil-tick stsndards $0 we are a trusted source of health information. Raising the proh'le of this disease 30 that people arg diagnosed sooner and this canc81 has a lesser Impact on them. Hosting a conference for people to learn rnore about clinical developments in th15 araa. Infoimatson on how people can live well with this cancer, and importantly to bring people together for peer-lo-peer support. Increa51ng the number of volunteers, In¢luding our local ambassadors so local meeting5 can take place around the country. Using all the resources we have available so that we are not held back because of financi81 constraint5. Our support is important to people, so we will ensura our small team Is correctly placed lo achieve the plans outlined in our 3-year strategy. Everything Ocular Melanoma UK has achieved has been through sheer dedication and a passion to make a real change in the lives of those affected by this dreadful Canr. Wè will continue until we have a worfd there people wath ocular melanoma can live. and liv8 11. Details of The Independent Examiner Tracey Pritchard BA FCA Membei of Chartered Accountant 255 Poulton Rtsad Wallasey Merseyside CH44 4BT 10
Ocular Melanoma UK Company Registration Number- 8013670 Trustees, Annual Report for the year ended 31 March 2024 Statement of the Directors Trustees. Responsibllltles The charity's tfU5tee5 are respOnsbIe for the preparation of the accounts In accordance wth the tèms of thè Companies Act 2006, the Charitle5 Act 2011 and thè Charities (Accounts and Reports) Regulations 2008. Noiwithslanding the explicit requirnent In the exlanl statutory regulations.th8 Charities IAccount5 and Report51 Regulatlons 2008. to piepare the financial statements In accordan with the SORP 2005. In ¥w of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring thern to follow curr8nt best tXactl and prepare the account5 according to the FRS 102 SORP (Statement of Recommended Piactice for Accounting and Reporting by Chariliesl 2015. las amended by the Bulletsn issued in October 2018 and applicable to all accountin9 periods baginning on or after 1st January 20191. lThe SORPI. . In particular, the Companies Act 2006 and charity law iequiie the Board of Trustees to prepare financial ststements lor each financial year which give a true and fair wew of the state of affairs of the ¢harity a$ at the end of the financial year and of the surplus or deficit of the charity. In prepanng those financial statement the Board Is roquirtrd to:. - preparè the accounts In accordance NTrith United Kingdom Generalty Accepted Accounting Practi Iunited Kingdom Accounting Standards and applicable lawl. select suitable accountitvj policies and apply them con51Stently." make judgements and estimates that are reasonable and prudent". prepare the financial statements on the going concem basi5 unl85S It 15 Inappropflate to presume that the charity will continue In business., state ether applicable accounting standards and ststernents of recornmended practsce have bèen followed, Subje io any material departures dis¢losed and explained In the financial statements.. The law qUireS that the trustees must not approve the accounts unless they are satisfied that th8y give true and fair view of the State of attairs of the charity afid of the surplus or deficit of the charity for the year. The Trustees a also responsible for maintaining adequate accounting records which di$¢lose wrth reasonable accuracy at any time the financial position of the chaTty and which are sufficient to show and explain the chanty's transactions and enable them to ensure that the financial st8lements Comply with the Companies A¢t 2006 and ¢omply Mrith re9ulats.ons made under the Charities Act They are also responsib for safeguarding the assets of the chanty and hence lor taking aSOnable steps for the prevention anil detection ol fraud and other IgularItIes. The Trustees are also sponsible for the contents of the Trustees, report. and the statutory responsibility of the Independent Examiner in relation to the Trustees, pOrt 15 lirnrted to examining the report and ensuring th8t , on the lace ol the pOrt. there are no material inconsistencies with the figures disclosed in the financial stalernent5. 11
Ocular Man0m1 UK Company Reglalratlon Numbw- 8013670 Trust•ts' Annual R•port for th• year •nd•d 31 Mar¢h 2024 IA•thod of pr•paratlon of ac¢ounts - Small oompany provlslons Tho linarthl 8t•t•m8nts ar• 6•t oul on pages 15 to 34. The finala1 $tatsments ha¥è boen w8paf•d implating ts FRS 102 SORP (StstMnt of PrnLce for nb.j ond Rwilry by Chnli881 2015. 186 amen ty the 1kntin 188u•d in Od(thr 2018 fdKI applKobkn to •ll Kc4)untitM p0d8 b•gMwvJ cn or aft•r 1qt 2019). Act 2C#J8. to efjmpen •ubJectto compgni98 roglme. Thos wa• •pwo¥od ty the t#)ard oftru61• ¢Jn 11 De(02024. MR8 C EDWARDS Cwector and TNS 12
Ocular Melanoma UK Report of the Independent Examlner to the Tru¥t•è$ of the ¢harltable Company on the accounts for the year endèd 31 2024 I repon io Ihe Trustees on My examination of the finanoal $latemenls of the charilable company on pa9es 15 10 34 lor the year ended 31 March 2024 have been prePad in accordance th the Chanlies Act 2011 Ilhe Acti and wlh the Finanual Reporting Standard 102. leffeclive 1st January 20161 as modified by FRS 102 SORP IS181emenl of Recommended Practice for Accounting and Reporting by Charilie$l 2015, las amended by the Bulletin issued In October 2018 and applicable to all accounting periods beginning on or after 1st January 20191. (The SORPI, pulshed by the Charity Commission in England & Wa$ ICCEWI , and under the hisloncal cost convention and a¢cwriliw policies sel on page 20 R08pe¢ttvo r•8poDsibiliti08 of tho Trustsos and the Independ•nt Exarninqf and thè ba$18 ot thv TOPOrt As described on page 11. you. Ihe Charitab cofflpany's Trustees. %tho are 81s0 Ihe DKector$ of Ihe Company for the purposes of Company law. are responsib for the preparation of the financial $181ements In accordance wlh the Companies Act 2006, Ihe Charilies Acl 2011 and all other applicable law and United Kirodom Generally AcTrpled Accovnling Praclice. applicable to smaller enlilies, and for being satisfied Ihal the financial slalemenls gwe a true and fair view The Twslees consider thai thè audrt requiremeni of Section 144111 of the Chantses Act 20t1 Ilhe Actl doe5 not apply, and that there is no re4uiremeni in the memorandum and artides of the charity for the conductin9 of an audit, and that the accoun1$ do not require an audit In accordance Ylh Fart 16 of the Companies Ad 2006 and Ihal no member or tnembÈrs have requesied an 8udil pursuant lo Seelion 476 of Ihe Cornpanies Act 2006. As consequence. the Trustees have elected th81 the financial sl8lemenls be Subje lo independenl exarninalion. Having $81isfied myself that the financial slalemenls are not required to be audited under any legal provision. or olhemse, and are eligible lor independenl examination. it is my responsibility lo-. al examine the financial slalements of the charity unrter Section 145 of Act.. bl followlhe appliCae p[orU5 in IhÈ Direthons given by Ihe Chanty Commission under seclion 1451Sllbl of the Act. B451¥ of Ind¢p¢nd¢nt Examir1•S Statsmèiit amd stopo of work undortaken I report in respect of my examination of the charity's finana81 slalemnls carried out under $145 of the Act. In airying out my exaffiinalion, I have follod all Ihe applible Directions given by the Charily Comfflission under section 145lSllbl tsf the Atl seiiing out the dulles of an Independenl examiner In relation lo the conducting of an independent examinaiion. An Independent examinaiion Includes a review of the accounting records kept by the charitable company and ol the accounting systems employed by the charitable company and a companson of the financial sialemenls presented 1th Ihose records. 1181so Include5 consideralion of any unusual iletns or disd05ures in the financial siaiemenis. and seeking explanations from you, 3$ Tw51ees, concerning such mattets. The putpose of the examination Is lo establish as lar as possible that there have been rio breaches of charity 91tion and thai. on a iesi basis of evidence relevant lo Ihe amounts and disdosures Tnade, Ihe finanal slaleTnenis comply valh Ihe SORP. The procedures undertaken do not provide aN Ihe evidence that wuld be required in an audlt, and Infomialion supplied by Ihe Truslee5 in the course of the e¥arnination 15 not subjected lo audit tesls or enquiries and doe8 not cover èll Ihe mailers Ihal an auditor would consider in arriwing at an opinion. The planning and conduci of an audit goes beyond the lime assurance that an independenl examination can provide Consequenuy, I do nol expres5 an audit opinion on the view yiven by the financial statements. and In pariicular, I express no opirNon as lo thelher the firiancial sl8lemeni$ give a Irue and fair vi&w of the affairs of Ihe charity. and my report is limited to the fflaller5 sel out in the Siaiemenl below. I planned and performed my examination $0 as 10 $*18ty myself ihal Ihe objectives of the Independenl examination are achieved and before fin8lising Ihe report l obtained witten assurances from the Trustees of all malerial rnatter5. 13
Ocular M•lanom• UK
SW tt) the knit•iwA w Iha w ol my d•iPAd lt0. I hwe t4)mp1 my •x•muwlhx' •TrJ rAn
•¢
Ocular Melanoma UK - Statement of Financial Activltles for the year ended 31 March 2024 Statement of Financial Activitles (Including the Incomè and Expenditure Account for thè year ended 31 March 2024, as required by the Companios Act 2006} $ORP R•1 Cuirent year Unre5tricled Fundts Current year Restricted Funds Currontyèa Total Fund$ Prfor Year Total F¥nd• 2024 2024 2024 2023 Income & Elo*entS from.. Donations & Legacie5 Charitable activities Other trading a¢tsvitie$ Investments A1 42.133 325 45.317 520 61.OLNJ 103,133 325 45,317 520 100.037 141 28.754 238 Total incom• 88.295 61,000 149,295 129.170 Expenditure on.. Raising funds Chariiable a¢livilie$ B1 B2 2.972 90.800 2,972 147,011 1,144 139,831 56.211 Total txpenthture 93,772 56,211 149,983 140,975 Nei income for the year 15,4ni 4,789 16861 111,8051 Transfers behween funds 18,0251 8,025 Net inci)rne after transfer5 A-B 113,5021 12.814 111.8051 Net mov¢m¢nt In fund$ 113.5021 12.814 16881 111.8051 Reconctliation of fund$-. Total funds brought lornvard 54,910 23.793 78,703 90.508 Total lunds caled lotward 41,408 36,607 78.015 78,703 The 'SORP Ref indicated above is the clas5ificaiion ef In¢¢me sel out In the formal SORP documents. As wuired by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balante Sheet. A separate Slalemenl of Total Recegnised Gains and Losses is not required as this statement includes all recogni5ed gain5 1055es. All adivilie$ derive from ¢ontinuing operations The nots$ attach•d on pag•s 20 to 34 fomi an integral part of these accounts.
Ocular Melanoma UK- Statement of Financial Actlvlties for the year ended 31 Mar¢h 2024 Oeular Melanoma UK- Analysis of prior year total funds. as required by paragraph 4.2 of the SORP PiOr Y•ar PiioTYear Total Funds SORP Ref Unrnktrittd Funds R4striCtd Funds 2023 2023 2023 In¢ome & End¢>vmients from.. Donat5 & Legacie$ Charitable aclivilie$ Other trading a¢llthes Investrnent$ Al 34,837 141 28,754 238 65,200 100,037 141 28,754 238 T¢xo1 Income 63,970 85,200 129.170 Exppndllure on: Raising funds chaiitab actNilies B1 B2 1.144 98.424 1.144 139.831 41,407 Total expendlture 99,%8 41,407 140,975 Net gain8 on nveslrnents Net Income for the year 135.5981 23.793 111,8051 Tfansters between fund5 Net Incom8 after tTan5f¢rs 135,5981 23.793 111,8051 m¥veme*rt In funds 135,5981 23,793 111.8051 Reconclllation of lunds'.- T•1 lund$ brtsugm loar 90,508 90,508 Total funds ¢arrled foTrward S4,910 23,793 78,703 16
Ocular Melanoma UK - Statempnt of Financial Activities for the year ended 31 March 2024 Ocular Melanoma UK- Rèsources applled In the year ended 31 March 2024 lowards fixed assets for Charlty use:. 2024 2023 Funds generated in the year a5 detailed in the SOFA Resources applied on functional fixed as$&ts Other app11cation5 of fund5 16881 111,8051 14271 N•t r•sources available to fund charitsble activitie$ 688 12,232 The resource$ applied on fixed assets for charity use represents the cost of addition$ les$ pro¢eed$ of any disposals. Thè notes attached on pages 20 to 34 forni an integral part of th•sè accounts. Movements Sn revenue and capital funds for the year ended 31 March 2024 Rèvenue accumu1¥4ted funds lJnto¥tri¢t• Fund8 2024 R•5trlcted Total Funds Last year Toial Fn 2023 Fun¢J$ 2024 102 Accumulated funds brought fmar 54.910 23,793 78.703 90,508 Recognised gains and losses befo tran$fers 15,47TI 4,789 16881 111.8051 49,433 28.582 78.015 76,703 IFrom)O unrestricted revenue funds 18.0251 8,025 Closlng revonu? funds 41.408 36.607 78,015 78,703 Summary of funds Unr•8¢rl¢tsd and De8ign•ted lund 2024 Total Last Ye•r Total Funds Funds 2014 2024 2023 Revenue accurnulaled funds 41.408 3S.607 78.01S 78.703 The notès atlached on pages 20 to 34 fom? an integral part of th•s• aecounts.
Ocular Melanoma UK - Statement of Flnancial Activitles for the year ended 31 March 2024 Ocular Melanoma UK Income and ExpendEture Account for the year ended 31 March 2024 as required by the Companies Act 2008 2024 2023 Income Inctsne from operations Investment income Interest receivable 148,775 128.932 520 238 Gross income in the year befove •xc•ptional Item$ 149,295 129,170 Gross income in the year including •X¢Wional Iiem$ 149.295 129.170 Expenditure Charitable expendrture, excluding depreciabon and amortisalion Deprecotion and amorDsaiion Fundra151ng costs Go¥emance costs 145,598 243 2,972 1,170 108,514 529 1,144 30,788 Total expenditure in the Or 149.983 140,975 Net in¢om¢ l)efor* tox In the financlal year 16881 111,8051 Tax on surplus on ordinary actlI1eS Net In¢ome aft¢r tax In Nnanclal year 111.8051 R•tslnèd $urplus for th• flnanclal y•ar 111,8051 All actiwlies derive from continuing operations In accordance with the prowsiens of the Companie5 Act 20(6. the headings and 5ubheading5 used in the In¢ome and Expenditure account have been aijapled to reflecl the $pe¢ial natu of the charity's adivitw. Th• not•s attach•d on pages 20 to 34 fomi an integral part of these accounts. 18
O(ul•r M•l•A•m• UK- B•l•n•• 8lw•ta •t 31 lJl•r•h 2024 Notei4•f 10 A2 481 B1 12 A2 2.10B 2,108 n2n 77238 79211 7B.222 17 D2
S.IYJ7 23.7513 17 03 41,408 54,910 A1408 -11 Ico4mrf2024 19
Ocular Melanoma UK Notes to the Accounts for the year ended 31 March 2024 1 Ac¢ounOng pollel•$ Poli¢i8s r•latlng to the ProdtIOn olthè a¢eounts. Basis of preparation and accounting convention The accounts have been popared on the a¢cruals ba$i%. under the histor84 cost convention. and In accordance with the Financial R8POrting Standard 102, leffeclive 1st January 20161 and 'FRS 102 SORP Islaternent of Recommended Practice for A¢counling ar RetM)rting by Charilie$l 2015. las amended by the Bulletin Issue¢S In October 2018 and applicable te all accounting periods beginning en or after 1st January 20191, IThe SORPI, published by the Charity Commission in England & Wale5 ICCEWI . effective January 2016. and in accordance with all applicab law In the charity's iurisdi¢tion of reglstralion. except that the ¢harity has prepared the financial slalement5 in accordance with the FRS 102 SORP (Slalement of Recommended PractiTr for Accounting and Reporting by Chantiesl 2015, las amended by the Bulktin issued in October 2018 and applicable to all a¢¢ounting periods beginning on or after 1st January 20191. (The SORPI, in preference lo the previous SORP, the SORP 2005, which has been withdrawn. notwithstanding the fact that the extant slalutory regulation5. the Charities IAccounts and Reports) Regulations 2008 refrr explicitly to the SORP 2005. This has been done to accord with current best practice. Ri$ks and fthure assumptlong The charty 1$ a publi¢ nefit entty. The Management Committee has reviewed the major fisks to which the charity has been exposed. Where appropriate, systems or procedures have been esiab115hed lo tniligate the risks Ite ¢harity fo¢e$. Our Regional RepresenlalNes are each issued with the Ocular Melanoma UK Representative Handbook and are invited to allend a trainirrfJ session. Financial ¢ontrol risks are minimised by tt)e imp*mentation of procedures for 8Uthorisalion of all transaclioTrs. Accounting for dBforr•d incom• and incomg receivgd in advart¢¢ Wher? ternis and condits.ons rekgling to inceme have not been met or uncertainty exisls a5 10 whether the charity can meet any leTrn5 or conditlDnS Othetwisè within its contro1. Income Is not recognised but Is deferred as a Iiabilty until it is probable that the terms or conditions Imposed can be mel. Any grant that is $ubjecl to perforrnance-related conditions ceIved in advance of dèlivering the goods and semees reguired by that condition, or is subject lo unmel conditions wholly outside the control of the recipient charity, is acceunted for as a liability and shown On the balance sheet as deferred inc(Ime. Deferred income is oleased to Income In the reporting period In which the pertormance-relaled or other condition5 that limit recegnilion are mel. When incorne frTrm a grant or donation has not been reco9nised due to the conditions apptying to the grft not being wholly within the control of th8 recipient chanty, it is disclosed as a contingent a55el rf receipt of the grant ur donation is probable once those condition5 are Mel. Where time related condrtions are Imposed or implied by a funder. then the income is apportioned to tr)e time periods concerned, and. where applicable. 15 accounted for as a liability and shown en the balance sheet as deferred incorne. When grants are received in advance of the expenditure on Ihe a¢iivity funded by Ihem. but the a no $pecifit tme relatsd conditions. then the income Is not deferred. Any c¢ndilion Ihat allows for the recovery by the donor of any unexpended part of a grant do&s not prevent recegnits'on of the income concerned, but a liability te any rep8ymenl is recognised when repayrrEnt becorne5 piobab4e. 20
Ocular Melanoma UK Notes to th9 Accounts for the ygar ended 31 March 2024 Donated go¢)ds, facllftles and 8ervice5 Donaled fixed assets are re¢o9nised at the current fair value. Al $u¢h donations are recognised a5 donation inc(The, and debited to fixed assets. Donated goods that are not fwed assets are actwnled for at a tsir value. unless it is IMpracCal to reli8bly measure the value of the donated Items. In the absence of any direct e¥Klence ol fair value af donated goods, then a value is derived from the cost of the Item to the donor or. in the case of 9{d8 that are expected to be sold. the estimated resale value after deducting any anliupated costs of sales. If Il Is Impracticable lo rneasure the fair value of goods donated for resale, or the costs of valuatson outseigh the t*nefits. the donated goods are recognised as income when sold, with an eqvlvant amount being recogni5ed a$ an expense. The costs of 9oods donated for d151ribulion lo beneficiaries Is deetned to be the fair value of those goods upon receipt When the goods are distributed freely or for a nominal e0n51deral0n, Ihen the carrying amount 15 adjusted at the lime of sale, lo the value al the point of distribution and the adjustment Is shown as a ¢o$t of donations madÈ. The Carrylng amount Of any stock hek1 for distribution is assessed fer impairment at the reporting dale. Al donated goods are reco9nised as donation income, and debited to trading stock. When trading $itsck 1$ $ubsequently so. or appropriated to rDeet an expen$e, then the Cary1r value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for con5UrnPtion by the charity are included in'lega¢ie$ and donations,. Go¢xJs donated for res# are included In 'ln¢otnè from other trading activitie$. The cost of any stock of gwds donated for distribution lo beneficiaiie$ 15 deemed to be Ihe lair value of those gifts at the titne of their retèipt. If thè goods held are to be distributed fre&ty or for a nominal consideration. then the carrying amount is subsequently adjusted lo reflect the lower of deerned c05t adjusted for any loss of Servi potential and rÈpiacement C051. Replacernent C051 Is the economic cost In¢uffèd if the charity was to replace the se potential of the donal goods at its own expense in the most econemic manner. Donated services and facilit5 (including seconded $tsff aThJ use of property) are in¢lutled in the a¢Unts on the basis of the value of the gift lo the charity. All donated services and facilities are recognk4ed a5 donation in¢tyne when re¢eived. {proded tt)e value of the grft can be measured reliably) and tOgnISed a$ an expense with an equlvant value. Polic$ r•lallng to assels, liabilities andprovisions and oth•rmatters. Tangible fixedas5ets Tangible fixed assÈl$ 2re measured at their original cost value. or subseqnI revaluation, or rf donated. a5 described above. Cost value includes all costs expended in briThJing the asset into 115 Intended wotking conditron. Depreciation has been provided at the followin9 rates in order lo write off th8 assets lo their anticipated residual value over their estimated useful INe$. Plant and rnachinery over 3 years A regular annual review gf the likelihood of assèt Impairment is undertaken. Stocks and work In progress Stvck is valued at the lower of ¢osl and net 011$able value. Fund Accounting Unrestricted funds are available for use ai the di$¢retitsn of the trustees in furtheran¢e of the general objectives of the ¢harity. There are no endowm&nl funds. 27
O¢ular Melanoma UK Notes to the Accounts for the year ended 31 March 2024 2 Liability to taxation The Trustees tonsider that the ¢harity satisfies the tests sel out In Paragraph 1 Schedule 6 of the Finance Act 2010 for UK ¢orporalion lax purposes. Accerdingly. the Charity 15 Potentially exernpl from laxalion in respect of income or capital gains received within categories covèred by chapter 3 part 11 of the Corporation Tax Act 2010 or Se¢bon 256 of the Taxation of chargeab Gains Act 1992. to the extent that such income or gain$ are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax Is not recoverabk by the charity. and 1$ therefo included In the revAnt costs in the Ststement of Financial Aclivits"8s. 3 Winding up or dissolution of the charty If vpon winding up or dissolution of the charity there rernain any assets. after the satisfaction of all debts and liabilities, I assets represented by the accumulated fund Shall be transferred lo Some other charitable body or dIeS having similar objec15 10 the ¢harity. 4 Signffi¢an¢e of finanelal Instruments to the charity's position There are rFO significant irnplicalions of such matters 5 N•t surplus before tax in the financial year 2024 2023 The surplu5 before tax in the finanual year Is stated after charging'.- DepClaon of owned fwed assets Trustees, Remurvèralion as detailed in no(8 8 Pension ¢osts 243 529 29,708 4,195 3.886 6 Staff costs and emoluments Sal•ry ¢o$ts 2024 2023 Gross Salaries excluding trustees and key management personnel Ernployer'5 o>perating ¢osls of defined contribution pension schemes Trustees. Remuneration as detailed in note e 97.851 66,373 3.886 4,195 29.708 Total salarie5, wages ond r¢lat¢d ¢ost$ 101.737 100,276 The average number of full time slaff employed in the year was estimated full trme £quivant number of all staff emptoyed in the year was Tho ¢$iimared equlvalentnumber olfull time Staff deployedin dill¢renta¢tlvltles In the year was... Engaged on ¢hari¢able activities The e$fim8ted full Ilme equlvalentnumber Df all staff •mployed as •bo Tl* details of remuneration paid lo trustees is shown in note 8 No employees o¢eived emments lexcluding penSn costs) in ex5 of £60.000 per annum. 7 Defined contribution pènsion schèmes Any Iiabililes and assets a55ociated with the scherne are shown und&r debtors and creditors. 22
Ocular Melanoma UK Notes to the Accounts for the year ended 31 March 2024 8 Remuneration and payments to Trusteès and pèrsons connèet•d with thém 2024 2023 Remuneration payable to trustses or conn•ctsdperson$ Trustee 1 28.293 Total rprnun¢ration More detailed Information in the man8Ment Comrnitte8 section On page 7. 25,708 9 Trustè•s' •xpens•s No tru51ee expenses were incurred, èither in the current or prior year. 10 Tangibl• flx•d assets Curr1 Yèar Land and Bulldlngs Plant & Machlnery Motor Vehltles Totsl ost At l Npril 2023 Additions 3.552 3,552 At 31 March 2024 3.552 3,552 Oepr8ciation At 1 April 2023 Charge forthe year 3.071 243 3,071 243 At 31 March 2024 3.314 3.314 Net book value At 31 March 2024 238 238 At 31 March 2023 Prior Year Land and Bulltllngs Plant & Ma¢hlnery Motor Vehi¢le$ Total C05t 01 April 2022 Additions 3.125 427 3.125 427 01 Aprll 2023 3,552 3.552 Depr¢¢latlon 01 April 2022 charge for the year 2.542 529 2.542 529 01 Aprll 2023 3.071 3,071 Net book value 01 April 2023 481 481 01 April 2022 583 583 23
Ocular Melanoma UK Notes to the Accounts for the year endod 31 March 2024 11 Stocks & Work In ProgmS$ 2024 2023 Stecks before write down8 2.108 2,108 2.108 2,108 12 Debtors 2024 2023 Pfftpayments and a¢¢rued intome 13 Cr•dltors: amounts falllng due withln one year 2024 2023 Trade credrters AccTua15 162 960 1.122 14 In¢ome and Expendbtur• a¢count summary 2024 2023 Al 1 April 2023 Surplu5 aftertax for the year 78.703 16881 90.508 111.8051 At 31 March 2024 78,015 78.703 15 No related party transactio No Iruslee er other person related lo the charity had any personal Inte$1 in any Contract or tran$aclion entered Into by the charity during the year. 16 Particulars of how particular funds are repre¥ent•d by assèts and Ilabllltl•s At 31 Mar¢h 2024 Unregtrlctod D•5i9nated Restricted Totsl funtts lunds Funds Tangible Fixed Asse15 Current Assets Current Liabilitie$ 238 42,774 11,6041 238 79,381 11,6041 36.607 41.406 36,807 78,015 At l Awil 2023 Unro¥trl¢t•d luthds P•slgnat•d fund5 Rgstrlcted funds Total Fund Taryibte Fixed A55ets Current Assets urrent abIlle9 481 55.551 11.1221 23.793 11.1221 S4,910 23.793 78,703 24
Ocular Melanoma UK Notps to the Accounts for the year ended 31 March 2024 17 Change in total funds over the yèar as shown in Not• 16 , analysèd by individual fund$ Fynds brought M¢)vement in forward from funth in 2024 2023 Tr•osf•rs fovw4rd to 2025 lunds in 20Z4 Sè• Not• 18 Unrestri¢t•dandde$lgnoto(I funds.". Unrestricted Reven Fund5 $4,910 15,4771 18.0251 41,408 Total unrestricted and de$ign•ted funds 54.910 5,477 8,025 41,408 R$tri¢t¢d fvnds... Pabent Education & ÉvenlslAnnual Conference) Patient fokjer Patsent Informatien lo Plk Standard Re$our¢es HCP Trial Database Helpline Advisor Role and Support Pyschological Support Educational Event 7.167 7,167 3,675 1,883 2,333 2,333 10,$44 4.839 3,833 3.675 9.766 17.8831 2.333 2.333 12.2961 16981 3.833 7.707 2.645 5.133 2,892 Total restricted funds 23,793 4,789 8,025 36,607 Total charlty funds 78,703 16861 78.015 18 Analysls of movements in funds over the year as shown in Note 17 Othev Galns & Movement In Losses fund5 lttcome Expenditure 2024 X24 2024 2024 Unrestritted and deslgnatedfunds... Unrestricted Revenue Funds 88.295 193,7721 15,4771 Re$tri¢i*d fvnd$.'. Re51ricled Fixed A55et Funds Reslricled Revaluation Re5erwe Conference and educational events Patient folder PaInI Infomialion to Pl1Ck stsndard Resource5 HCP Tri81 Database Helpline Advisor Role and Support Py5chobgical Support Educalionsl Event 21.000 113.8331 7,167 7.833 2,333 2,333 15.333 8,335 3,8 115.7161 17.8831 2,333 2,333 12.2961 16981 3,833 117,6291 19.0331 149.295 1149,9831 16881 25
Ocular Melanoma UK Notos to the Accounts for the year ended 31 March 2024 19 The purposes for which thè funds a¥ Unre$trici¢d anil deslgn8ted lund5.'. These funds are held for the meeting the objectives of the charty. and to provide re5errf8s for future actswlies, and, subject to charity legk4lalion, artr free fmm all $triCh1}n$ on their use. Unrestricted Revenue FuJ$ Restrict8dfunds.-. Re$lricted funds are funds that donots have given for a particu18r purpose andlor project as outlined by donors and may include other connected costs. The aim and use of each re$lri¢ted furKJ are detai In the note$ of the financ481 statements. Restricted Revenue Funds". 20 Ultimate controlling party The charty 15 under the control of 11$ legal members. Every member of the charity is obliged lo mnlribute 8uch amount as may be required not exceeding £10 te the assets of the eempany in the event ef its being wound up while he cr She 1$ a member, or wrthin one year after he OT She ¢ease$ to be a member. 26
Ocular Melanoma UK Detallèd analysis of income and xndItUr0 for the year •nded 31 March 2024 as required by the SORP 2015 This anatysls is classsird by Conventional nomlnal descrlptsons and nol by activity. 21 Donatlons. Grants and Legacies Current y•1 Cvrront year R8strlcied Fund5 Cuiient year Total Fund8 Prior Ye4r Funds 2024 2024 2024 23 Small donations individually than £1000 Just Giving- anonymous denors 21,996 21.996 19,232 2,329 2.329 CLS UK 1,000 1.000 In Memory 13.786 13,788 13,387 Ti)tsl dtsnatlons and 9ifts Irom Individuals 39,111 39,111 32.619 DonatSons and gift5 from individuJl$ Iln¢lude HMRC refunds on glft alded donatlonsl- Prlor Year anatysis Prior Year LIDre¥tricted Futtd# Prior Year Restricied Funth Pvioi YNr Toi41 Futhd$ 2023 2Q23 2023 Prlor y¢ar 32,619 32.619 Cuvrnt yèr uthro8tri¢d Funds Curr•)t yèar Currenly¢ai Total Fund Prior Year Total Funds 2024 2024 2024 2023 Legactos receivable Late CH 2,218 Yotsl legacies Tecefjvable 2.218 Legacies receivablo- Prior Yoar analysis Prior Year Unieslilcted Fund5 Prior Year Reslrlcted Fund5 Prior Yr TOIAI Fund• 2023 2023 2023 Prlor year 2.218 2.218 27
Ocular Melanoma UK Detailed analysis of incom¢ and èxp8nditure for the year ended 31 March 2024 as required by the SORP 2015 Currontyea¥ Unre¥thcted Fund¥ Currenty••t Restrict•d Fund$ Currént y••r Total Fundg Prlor Year ToiAI Futhds 2024 2024 2024 2023 ArThd Clark 1,000 Detath System$ Ltd 11,fMIO 13,10D Immunocore Limited 32.LNJO 32,000 41,1 National Lottery 10.000 Vision Foundaiion 9.000 9.000 Alan BosweR Gharity ALA 3.022 3,022 Souter Charilabk Trust 3,000 3,000 Trisalus Life Science 3,000 Ideya Bios¢pen¢e$ 3.orK) Total private sector revenue grant5 3,022 61.000 64.022 6S.200 Revenue grants and donations from non public bodies Ilnclude Gfft Ald donat11) fri)m $ubsidiarie$l Year analy51S . Prior Prior Year Prior Ywr Prlor Y•ar L¢nrestricted Fund¥ R•81iict•d Ftsnds Total Fund 2023 2023 2023 PrSor Year 65,200 6S,200 28
Ocular Melanoma UK Detsiled analysls of Sncome and expenditure for thè yoar gnd•d 31 Mar¢h 2024 as r•qulred by the SORP 2015 Total Donatlons, Grants and Legacles UnT••lricted Fund Restricted FuDd8 Curnt Ypor T•twl Fund$ Prior Ye•f T¢)t•l Fund CuTrentyMr 2024 2024 202 Z023 Total Donations. Grants and Lega¢l$ A1 42,133 61,000 103,133 100,037 UrbrosiriCt•d Funds Rèsirleted Funds Prlor Y4ar Total Funds 2023 Priory•ar 2023 2023 Totsl Donations, Grants and Ltqacles Al 34,837 65.200 100,037 22 Income from charitable a¢tiviti•¥ - Trading A¢tiviti¢$ Currentyr CU¢t ye•v Vnrgtvlttèd Funds Curresrt y••r RèBtrieted Funds urtytrt y4r Totbl Funds Prior Y•or Total fund5 2024 2024 2024 Z023 Primary purpose and ancillary trading Sale of goods and service5 In accordance with the ¢hariVs objects 325 325 141 Totsl Prbmary purpose and ancillary tradlng 325 325 141 Prioryear Prior Year Unfo¥tri¢t•d Fuids Prlor Year Re•tri¢tod Funds Prior Year Total Fund• 2023 2023 2023 Primary purpose ond an¢lllary tradln9 Sale of goods and semces In accordance with th8 charitys objects 141 141 Total Prlmary pvrpose and anclllary tradlng 141 141 29
Ocular Melanoma UK D•tsll•d analysls of Income and expenditure for the year ènded 31 Mareh 2024 as required by th• SORP 2015 23 Total Income from charitable activiti85 Cvrr•Dtyear Unrestricte Funds Cumnt year ogtrieted Fuhds CuThent year Toi•l Funds Prior Year Current year Total Fund8 202 2024 2024 2Q23 Total income from charitable trading 325 325 141 Total from charitable activities A2 32S 325 141 Income from ¢harit¥blo a¢tivltles- Y¢or analysls Prior Year Unrestricted Funds Prior Y••1 R•6tricted Fund¥ PvlotY••r Total Funds 2023 2023 2023 Total incorne from chaFitable tradiNJ Income from funders 141 141 141 141 30
Ocular Melanoma UK Dètsilèd analysbs of income and expenditure for the year ended 31 March 2024 a$ r•qulr•d by SORP 2015 24 Income from oth¢r, non ¢harltsbl•. tradlng actlvlt5•s CurrEntye4r unresiricted Fund Crrent year Ilesincte Fund Cvn•nt yèar Total Fund5 Prior Year Total FutKI$ 2024 2024 2024 2023 Income from fundra18ing events 45,317 45.317 28,754 Totsl other actlvltle& A3 45.317 46,317 28,754 Income from olhBr, non ¢haritaWè, trading aclivitios- Prior Y8aT analy$ls Unrestricted Fund5 Restricted Funth T¢AI Fundi Prfor Year 28,754 28.754 31
Ocular Melanoma UK Detailed analysi¥ tsf in¢om¢ •nd expenditur• for th• yèar ¢nd¢d 31 March 2024 as required by the SORP 2015 25 EXpendIre on charltable activities- Oirect spending Curreniyear unrestricts Funds Currentyfjar •siThctell Funds Currontyo•r Totsi Fund$ PrityYY¥ar Total Funds Currpni Year 2024 2024 2024 202J Gross wages and SalarS- charita8 66,951 30,900 97,851 66,373 Defined ¢onlribulion pension $ts chantable aCtiltIeS Travel and Subsi5tence- Charitable Acliwtie5 Marketing and advertising of charitable semces Charitae actiwties costs Training costs 3,88e 3.886 4.195 747 747 1,079 118 118 1,595 1.395 25.311 26,706 21,02S Total direct Spending B2 73.097 56.211 129,308 94,267 I t1 expenditure in the prior year was unrestricl8d. Prlor Yeai L*nre¥tri¢t• Funds 2023 Prlor Year •¥tri¢tOd Fund5 Prlor Yr Total Funds Prior Year 2023 1023 Gross wages and SalarS- charitable 42,310 24,063 66,373 Defined contribution pension costs cfvaritab activit$ Travel and Subsi8tence- Charitable Actiwties Marketing and advertisin9 of chantab semces 4,195 4,19S 1,079 1,079 1,595 1.595 Charit8bie activities costs Training costs 3.681 17.344 21,025 Totsl dlrect spending B2a 52,660 41.407 94,267 32
Ocular Mglanoma UK Oetailed analysis of Ineom• and expenditure for the y•ar tnded 31 March 2024 as r•quir•d by th• SORP 2015 26 Support ¢o$ts for charitable activities Cuwrent yeav unretstritt Funlts Current yeaw •stricte4J Funds y••r Prfjor Y••i Tot41 Funds Total Fund5 Currént Yéar 2024 2024 2024 2023 Employee cosls not includedin dif•Ct costs Recruitment expenses Adminislratiye overheads Telephone, fax and intemet Stationery and printing Membership sub8criplions SOftrare licences and exn585 Sundry expenses Insurance 256 256 892 1.885 597 2,662 2,682 1.88S 597 2,662 2.682 954 2,262 4,094 907 907 862 Professional fees paid to advisors other than the auditor or examiner Accountancy fees other than examinabon or audit fewJ 1,772 Other legal and profes$ional 1,772 1,469 5.363 5,363 3,119 Flnancial costs Bank charges Depreaation & Arnortisation in total for the period 132 132 205 243 243 529 Support costs before reallocation 16,499 16,499 14,730 Totsl support costs - Curr•nt Year 16,499 16,499 14,730 The basis of allocation Of ¢osts beNveen aciiwlies Is described under ac¢ounting policies I the expenditure In the prKir year wa$ unreslri¢led. 27 Other Expenditure- Governance costs Curront yoor unr•stri¢tstl Funds Cuvrgnt ywar •$trl¢t•d Funds cUt yeAr Tolal Fund• Prkn Year Total Funds Current Year 2024 2024 2024 2Q23 Indendent Examinerfs fee5 Trustees, Remuneration as detatkd in note 8 1.170 1,170 1.080 29,708 Totsl Goveinance costs 1.170 1,170 30.788 I the expenditure in the piior year wa$ unrt$lricled. 33
Ocular Melanoma UK D•talled analysis of Incomè and expenditure for th• y•ar ended 31 March 2024 as required by the SORP 2015 28 Totsl Charltsble exp•ndEiur¥ Cuwrerbt yèav unre6trirt411 Funits Ct y•ar •¥tri¢l• Furbd$ Cutt•nt y•ar Total Fund& Prlor Y•8r Total Fund& Currenl Year 2024 2DZ4 2D24 2023 Total direct spendir Total Charitable trading costs Total support costs Total Goveman¢e Costs B2a 73.097 56.211 129.308 34 16.499 1,170 94,267 46 14,730 30,788 B2b B2d 82¢ 16.499 1.170 Totzl charitablo gXPBnthtur• 90,800 $6,211 147.011 139.831 Prior Y••r Unresirict•l Fvnd prtorY•ar ostritl•¢ Fund# P1 Y•4r Tolal Funds Prior Year 202J 2023 2023 Total direct spending Total charitable trading costs Total support C0$15 Total Govemance costs B2a B2b B2d B2è 52.860 46 14.730 30.788 41.407 94.267 46 14.730 30,788 Total chartiablo •xponthiur¢ B2 98,424 41,407 139,831 29 Exp•ndlturo on raising funds and costs of investment management Cuttent year unrÈstritted Funds Cuiient year £strieted Funds cuTnt year Tot•1 Fund Prior Year Totsi Fund¥ Current Yéar Z024 2024 2024 2023 Cost of fundraising actiiti8S 2.972 2,972 1,144 Total fUFraising ¢9Sts Al the eKpenditure in the prr year was unrestricted. B1 2.972 2,972